Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02947984 · ClinicalTrials.gov registry record · Phase 3
Proton/Photon Rt - Benign Meningiomas(P92-13)
A Phase 3 study of Benign Meningioma, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- Phase 3
- Development phase
- 44
- Enrollment target
- 1
- Study location
NCT02947984: Completed Phase 3 study of Benign Meningioma, sponsored by Massachusetts General Hospital.
NCT02947984 is a Phase 3 study of Benign Meningioma that has completed, run by Massachusetts General Hospital. The registered enrollment target is 44 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02947984, a Phase 3 study of Benign Meningioma, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 44 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine the best radiation dose for participants with meningioma that has grown back after previous surgery, or which the surgeon has been unable to remove completely. This research study is designed to determine whether a higher dose of radiation will decrease the likelihood that the tumor will grow back, compared to the probability of re-growth that occurs after standard radiation doses.
Primary Outcome
The number of participants surviving at the given time point. Progression free survival (PFS) is measured from the starting date of radiation therapy and analyzed by intention to treat. PFS is measured until the earlier, date of death or development of radiologic progression, and is otherwise censored at the last follow-up for progression-free patients still alive.
Conditions Studied
Interventions
- RADIATION Standard Treatment
- RADIATION Higher Dose
Study Locations (1)
Massachusetts
- Massachusetts General Hosital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 1999-03 |
| Est. Completion | 2016-09 |
| Phase | Phase 3 |
What the finished NCT02947984 record still lists
NCT02947984 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 44 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (94% lower).
The record links to 1 condition, with Benign Meningioma appearing as the primary indexed condition, and to 2 interventions - of which Standard Treatment is the first listed.
NCT02947984 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT02947984 about?
NCT02947984 is a clinical study titled "Proton/Photon Rt - Benign Meningiomas(P92-13)". The purpose of this study is to determine the best radiation dose for participants with meningioma that has grown back after previous surgery, or which the surgeon has been unable to remove completely. This research study is designed to determine whether a higher dose of radiation will decrease the ...
What is the current status of trial NCT02947984?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 44 participants. The study started on 1999-03. Estimated completion is 2016-09.
What conditions does trial NCT02947984 study?
This clinical trial studies the following conditions: Benign Meningioma.
What interventions are being tested in trial NCT02947984?
The interventions under investigation include: Standard Treatment (RADIATION), Higher Dose (RADIATION).
Who is sponsoring clinical trial NCT02947984?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02947984 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02947984's enrollment target sits among peer trials
44 1874th of 2000 higher than 125 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02323945 · 44 participants · NA
Effects of Breathing Mild Bouts of Low Oxygen on Limb Mobility After Spinal Injury
- NCT03093909 · 44 participants · Phase 1
Study of Aerosol Gemcitabine in Patients With Solid Tumors and Pulmonary Metastases
- NCT03104491 · 44 participants · Phase 1
Inotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic Leukemia
- NCT03781765 · 44 participants · Phase 4
Stimulant vs. Non-stimulant Treatments and Reward Processing in Drug-naive Youth at SUD Risk
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia